Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povorcitinib in Inadequately Controlled Moderate to Severe Asthma
NCT05851443Phase 2Active, not recruiting
- Sponsor
- Incyte
- Start
- Jul 2023
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of povorcitinib in asthma (4 arms), sponsored by Incyte. Primary endpoint: Absolute change in pre-bronchodilator forced expiratory volume in the first 1 second at 24 weeks. Started Jul 2023; status: active, not recruiting.
02
Drugs
povorcitinib
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05851443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05851443.